All In Biotech

NDA 203388 · Genentech

Erivedge

Vismodegib · Oral · Hedgehog Pathway Inhibitor

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Jan 30, 2012

Approved uses

2

Original approval plus efficacy supplements

Registered trials

86

0 Phase 3, 11 recruiting

FAERS reports

8,927

3,811 serious, 998 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY ERIVEDGE can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. ERIVEDGE is embryotoxic, fetotoxic, and teratogenic in animals. Teratogenic effects included severe midline defects, missing digits, and other irreversible malformations [see Warnings and Precautions (5.1) , Use in Specific Populations (8.1) ] . Verify the pregnancy status of females of reproductive potential within 7 days prior to initiating ERIVEDGE. Advise pregnant women of the potential risks to a fetus. Advise females of reproductive potential to use effective contraception during and after ERIVEDGE [ see Dosage and Administration (2.1) , Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ] . Advise males of the potential risk of ERIVEDGE exposure through semen and to use condoms with a pregnant partner or a female partner of...

What it is approved for

From the label in effect Dec 2, 2024.

ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. ERIVEDGE ® (vismodegib) is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. ( 1 )

Mechanism: Vismodegib is an inhibitor of the Hedgehog pathway. Vismodegib binds to and inhibits Smoothened, a transmembrane protein involved in Hedgehog signal transduction.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jan 18, 2019 Supplement 12 · Efficacy LabelLetter
  • Jan 30, 2012 Original approval · Type 1 - New Molecular Entity · priority review NovelLetterLabelReview
1 products under this application
  • ERIVEDGE · VISMODEGIB 150MG · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vismodegib" as an intervention, any sponsor and status, largest first.

All 86 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • muscle spasms2,074
  • alopecia1,406
  • ageusia1,018
  • fatigue980
  • death757
  • dysgeusia748
  • weight decreased741
  • nausea722
  • decreased appetite708
  • diarrhoea476
  • constipation383
  • off label use383

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
20113
2012122
2013241
2014292
2015468
2016631
20171,465
2018869
2019773
2020710
2021663
2022741
2023674
2024666
2025385
2026223

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Erivedge (Vismodegib)

2024 spending

$117M

Beneficiaries

1,870

9,065 claims

Per beneficiary

$62,444

$474.32 per unit

View as table
YearSpending
2020$138,064,673
2021$140,212,165
2022$124,771,563
2023$102,945,428
2024$116,769,824

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 85 on PubMed

Sponsor: Roche (Genentech)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.